promising checkmate-142 data for second-line ipilimumab plus nivolumab in mcrc
Published 5 years ago • 287 plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
1:11
nivolumab/ipilimumab combination data promising in msi-h/dmmr mcrc
-
5:59
nivolumab plus low-dose ipilimumab promising for treatment-naïve msi-high mcrc | heinz-josef lenz
-
1:54
dr. lenz on updated data from checkmate 142 with nivolumab ipilimumab in mcrc
-
2:37
moving forward with results from checkmate-142 in msi-h mcrc
-
4:18
john leighton, md, comments on the outcomes of checkmate 142 in mcrc
-
2:32
dr. overman discusses updated findings of checkmate-142 in patients with msi-h mcrc
-
1:05
nivolumab and ipilimumab combination in frontline mcrc
-
1:11
checkmate-8hw: nivolumab and ipilimumab in msi-h/dmmr mcrc
-
2:00
checkmate 8hw: first-line nivolumab plus ipilimumab in msi-h/dmmr mcrc
-
1:03
dr. nelson on the checkmate-142 trial in msi-h/dmmr mcrc
-
4:31
checkmate142: checkpoint combination therapy in first-line colorectal cancer
-
0:59
checkmate 8hw: hrqol outcomes of nivolumab and ipilimumab in msi-h/dmmr mcrc
-
2:07
howard hochster, md, outlines the results of the checkmate 142 study in mcrc patients
-
5:19
i-o therapy in mcrc: ipilimumab nivolumab
-
2:33
updated results for nivolumab in msi-h colorectal cancer
-
2:02
hrqol findings from checkmate 8hw: nivolumab and ipilimumab in msi-h/dmmr mcrc
-
2:20
philip philip, md, phd, frcp, discusses the impact of the checkmate 142 study on mcrc
-
0:53
dr. lenz on the safety profile of checkmate-142 trial in crc
-
3:24
checkmate 8hw: nivolumab plus ipilimumab versus chemotherapy for metastatic colorectal cancer